Posted by Michael Wonder on 27 Apr 2022
Editas Medicine receives FDA rare paediatric disease designation for EDIT-301 for the treatment of beta thalassaemia
26 April 2022 - Editas Medicine today announced that the U.S. FDA granted rare paediatric disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassaemia.
The FDA previously granted rare paediatric disease designation to EDIT-301 for the treatment of sickle cell disease.
